Compare RVPH & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVPH | FLUX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 24.1M |
| IPO Year | N/A | 2019 |
| Metric | RVPH | FLUX |
|---|---|---|
| Price | $0.21 | $1.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $3.14 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.5M | 362.9K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,317,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.25 |
| 52 Week Low | $0.20 | $1.01 |
| 52 Week High | $1.47 | $7.55 |
| Indicator | RVPH | FLUX |
|---|---|---|
| Relative Strength Index (RSI) | 26.66 | 53.25 |
| Support Level | N/A | $1.41 |
| Resistance Level | $0.31 | $1.61 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 10.43 | 70.99 |
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.